Research to probe how Covid-19 affects people
The University has received nearly £5 million from the government’s rapid response call to tackle the coronavirus pandemic.
The £4.9 million investment will kickstart a new project that seeks to increase our understanding of Covid-19 and its impact on the body.
Researchers will collect samples and data from 1300 Covid-19 patients in the UK. The results will provide real-time information about the virus and could help to control the outbreak and improve treatment for patients.
Specifically, researchers will use the data to discover who in the population is at higher risk of severe illness, what is the best way to diagnose the disease. They will also probe what happens in patients’ immune systems to help or harm them when they contract Covid-19.
The team will also monitor the effects of drugs used in patients, calculate how long people are infectious, investigate if people are infected with other viruses – such as flu – at the same time.
Dr Kenneth Baillie, Academic Consultant in Critical Care Medicine, University of Edinburgh, said: “Covid-19 is completely new disease and presents so many unanswered questions. Through analysis of samples from 1,300 people, we can increase our understanding of how Covid-19 makes some people desperately sick. This in turn will help inform how we can best treat the disease.”
Dr Kenneth Baillie has secured funding from the Medical Research Council to work in partnership with Professor Peter Openshaw from Imperial College London and Professor Calum Semple from the University of Liverpool.
The MRC-University of Glasgow Centre for Virus Research (CVR) will also play a role in this project, undertaking whole genome sequence of the virus from samples. Dr Antonia Ho from CVR will coordinate recruitment of Scottish patients.
The team has been part of the International Severe Acute Respiratory Infection Consortium (ISARIC) for eight years and includes co-investigators from six UK universities and Public Health England.
Scotland’s Pharma Services cluster can deliver solutions for drug developers across the full value chain of therapeutic development. Find out more about Scotland’s pharmaceutical services, here.